Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo[1].
References
[1] Keir
ST, et al. Sym004-induced EGFR
elimination is associated with profound anti-tumor activity in EGFRvIII
patient-derived glioblastoma models. J Neurooncol. 2018 Jul;138(3):489-498. DOI:10.1007/s11060-018-2832-6 [2] Modotuximab. IMGT Database.
